We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Objective
To evaluate whether daily oral supplementation with yeast‑derived β‑glucan (#300 formulation) enhances mucosal antibody production (salivary IgA, IgM, IgG) in children with chronic respiratory problems, and to determine whether β‑glucan can strengthen mucosal immunity in a high‑pollution environment.
Methods
A randomized, double‑blind, placebo‑controlled clinical trial enrolled 40 children aged 8–12 years with chronic respiratory conditions living in a region with severe air pollution. Participants received 100 mg/day oral β‑glucan #300 or placebo for 30 days. Saliva samples were collected at baseline and day 30 using standardized Salivette procedures. Secretory IgA, IgG, and IgM were quantified via nephelometry. All children received identical diet, environmental therapy (climatotherapy, speleotherapy), and medical oversight.
Results
β‑glucan supplementation produced a significant increase in all measured salivary antibodies:
- IgA increased by 183%
- IgG increased significantly
- IgM increased significantly
In contrast, the placebo group showed declines in IgA, IgG, and IgM over the same period. No adverse reactions were reported. The β‑glucan used was a highly purified, insoluble yeast‑derived β‑(1,3/1,6)‑glucan (>85% dry weight).
Our take
Interpretation
Daily oral β‑glucan #300 appears to enhance mucosal immune function, particularly secretory IgA, which is central to upper airway defense. The findings suggest β‑glucan may counteract immune suppression associated with chronic respiratory disease and environmental pollution. The mechanism is consistent with known β‑glucan pathways involving macrophage and dendritic cell activation, leading to enhanced humoral responses.
Limitations
- Small sample size (n=40).
- Short duration (30 days).
- Conducted in a single geographic region with unique environmental stressors.
- No mechanistic biomarkers beyond antibody levels were assessed.
- Clinical outcomes (e.g., infection frequency) were not measured.
Implications
β‑glucan #300 may serve as a safe, low‑cost immunomodulatory adjunct for children with chronic respiratory problems, particularly in high‑pollution settings. The strong mucosal antibody response supports further investigation into β‑glucan as a preventive strategy for recurrent respiratory infections and as a tool to enhance mucosal immunity.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!